MedTrace Logo

Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

NCT02671864 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7200

Last updated 2023-03-06

No results posted yet for this study

Summary

Experimental data suggest that GLP-1 promote endothelial cell growth and angiogenesis which may have beneficial effects on the cardiovascular system but harmful effects on the retina . This project investigate the possible link between incretin therapy and Severe Diabetic Retinopathy. The prevalence of severe DR in patients exposed to incretin therapy (GLP-1 analogs or DPP4 inhibitors) is compared to that in non-exposed patients to these antidiabetic classes.

Conditions

Interventions

OTHER

1: incretin-based therapy

OTHER

2: other antidiabetic

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Centre National de la Recherche Scientifique, France

    collaborator OTHER

  • Collège de France

    collaborator UNKNOWN

  • University of Paris 5 - Rene Descartes

    collaborator OTHER

  • Pierre and Marie Curie University

    collaborator OTHER

  • University Paris 7 - Denis Diderot

    collaborator OTHER

  • Aix Marseille Université

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • GAUTIER Jean-François, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2022-04-11
Completion
2025-04-11

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02671864 on ClinicalTrials.gov